Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole vs paliperidone/risperidone in first psychotic episode using multi-omics biomarkers
2022-001582-12Phase 4Active
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) and psychosis comparing Aripiprazole arm with Paliperidone/risperidone arm (2 arms). Primary endpoint: Therapeutic response to aripiprazole or paliperidone. Started Jan 2023; status: active.
02
Drugs
aripiprazolepaliperidonerisperidone
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)psychosis
Beyond the preview
Go deeper on 2022-001582-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001582-12.